

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT(S)**

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/648,593
Filing Date	08/26/2003
First Named Inventor	FEI HUANG
Art Unit	1652
Examiner Name	SWOPE, SHERIDAN
Attorney Docket Number	D0273 NP

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	AA	Reeves, et al., "Identification of Pharmacogenomic Markers for Predicting Sensitivity to BMS-354825, a SRC/ABL Kinase Inhibitor", ASCO - May 15, 2005	
	AB	Clark, Edwin A, Ph.D., "Pharmacogenomics: Reduction to Practice", AACR - April 1, 2006	
	AC	Finn, et al., "Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/ "triple-negative" breast cancer cell lines growing in vitro", Breast Can. Res., Vol. 105, pp. 319-326 (2007)	
	AD	Huang, et al., "Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection", Cancer Res., Vol. 67 (5), pp. 2226-2238 (2007)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant